​

Pacira BioSciences (PCRX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Pacira BioSciences Revenue Highlights

Latest Revenue (Y)

$726.41M

Latest Revenue (Q)

$192.40M

Main Segment (Y)

Product

Pacira BioSciences Revenue by Period

Pacira BioSciences Revenue by Year

DateRevenueChange
2025-12-31$726.41M3.63%
2024-12-31$700.97M3.85%
2023-12-31$674.98M1.22%
2022-12-31$666.82M23.14%
2021-12-31$541.53M26.04%
2020-12-31$429.65M2.05%
2019-12-31$421.03M24.83%
2018-12-31$337.28M17.67%
2017-12-31$286.63M3.71%
2016-12-31$276.37M10.99%
2015-12-31$249.00M25.97%
2014-12-31$197.67M131.05%
2013-12-31$85.55M118.89%
2012-12-31$39.08M149.12%
2011-12-31$15.69M7.74%
2010-12-31$14.56M-2.96%
2009-12-31$15.01M7.76%
2008-12-31$13.93M-

Pacira BioSciences generated $726.41M in revenue during NA 2025, up 3.63% compared to the previous quarter, and up 169.07% compared to the same period a year ago.

Pacira BioSciences Revenue by Quarter

DateRevenueChange
2026-06-30$192.40M8.47%
2026-03-31$177.38M-9.90%
2025-12-31$196.87M9.67%
2025-09-30$179.52M-0.87%
2025-06-30$181.10M7.21%
2025-03-31$168.92M-9.79%
2024-12-31$187.25M11.08%
2024-09-30$168.57M-5.31%
2024-06-30$178.02M6.53%
2024-03-31$167.12M-7.79%
2023-12-31$181.24M10.56%
2023-09-30$163.93M-3.27%
2023-06-30$169.47M5.69%
2023-03-31$160.34M-6.75%
2022-12-31$171.96M2.68%
2022-09-30$167.47M-1.15%
2022-06-30$169.41M7.23%
2022-03-31$157.99M-0.76%
2021-12-31$159.19M24.64%
2021-09-30$127.72M-5.80%
2021-06-30$135.59M13.92%
2021-03-31$119.03M-9.12%
2020-12-31$130.97M11.48%
2020-09-30$117.48M55.60%
2020-06-30$75.50M-28.56%
2020-03-31$105.68M-13.67%
2019-12-31$122.42M16.95%
2019-09-30$104.69M2.03%
2019-06-30$102.60M12.37%
2019-03-31$91.31M-4.00%
2018-12-31$95.11M13.98%
2018-09-30$83.45M-0.78%
2018-06-30$84.11M12.73%
2018-03-31$74.61M-5.65%
2017-12-31$79.08M17.44%
2017-09-30$67.33M-5.07%
2017-06-30$70.93M2.38%
2017-03-31$69.28M-4.96%
2016-12-31$72.90M6.65%
2016-09-30$68.36M-1.85%
2016-06-30$69.64M6.36%
2016-03-31$65.47M-5.55%
2015-12-31$69.32M11.43%
2015-09-30$62.21M5.18%
2015-06-30$59.15M1.43%
2015-03-31$58.32M-5.63%
2014-12-31$61.79M18.72%
2014-09-30$52.05M10.35%
2014-06-30$47.16M28.65%
2014-03-31$36.66M9.23%
2013-12-31$33.56M44.31%
2013-09-30$23.26M35.69%
2013-06-30$17.14M47.93%
2013-03-31$11.59M10.88%
2012-12-31$10.45M23.14%
2012-09-30$8.49M-31.25%
2012-06-30$12.34M58.18%
2012-03-31$7.80M84.36%
2011-12-31$4.23M7.00%
2011-09-30$3.96M8.80%
2011-06-30$3.64M-5.88%
2011-03-31$3.86M76.31%
2010-12-31$2.19M-51.65%
2010-09-30$4.53M48.35%
2010-06-30$3.06M-36.14%
2010-03-31$4.78M11.67%
2009-12-31$4.28M13.94%
2009-09-30$3.76M-

Pacira BioSciences generated $192.40M in revenue during Q2 2026, up 8.47% compared to the previous quarter, and up 113.90% compared to the same period a year ago.

Pacira BioSciences Revenue Breakdown

Pacira BioSciences Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22Dec 21
EXPAREL$575.13M$548.96M$538.12M$536.90M$506.51M
Product$722.85M$697.19M$672.25M$664.15M-
ZILRETTA$116.63M$118.09M$111.10M$105.52M$12.68M
Bupivacaine Liposome Injectable Suspension$6.91M$7.32M$3.34M$6.48M$3.61M

Pacira BioSciences's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (50.85%), EXPAREL (40.46%), ZILRETTA (8.20%), and Bupivacaine Liposome Injectable Suspension (0.49%).

Quarterly Revenue by Product

Product/ServiceJun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21
EXPAREL$147.82M$143.27M$155.78M$139.90M$142.92M$136.53M$147.68M$132.00M$136.85M$132.43M----------
ZILRETTA$32.65M$26.77M$32.98M$28.98M$31.33M$23.34M$33.12M$28.42M$30.71M$25.84M$28.70M$28.80M$29.26M$24.33M$27.97M$26.49M$27.42M$23.64M--
Product$190.49M$177.38M$196.87M$178.04M$180.35M$167.59M$187.25M$167.72M$176.39M$165.82M$179.76M$163.58M$169.47M$159.43M$171.59M$166.56M$168.58M$157.42M$126.79M$134.86M
Bupivacaine Liposome Injectable Suspension$3.22M$1.16M$1.11M$2.69M$508.00K$2.60M-$1.64M$3.15M$2.52M$1.10M$858.00K$695.00K$688.00K$1.01M$2.96M$956.00K$1.56M--
EXPAREL/bupivacaine liposome injectable suspension-----------$128.67M$135.13M$130.41M$132.64M$137.01M$129.21M---
Collaborative Licensing and Milestone Revenue-------------------$125.00K
Royalty------------------$931.00K$602.00K

Pacira BioSciences's latest quarterly revenue breakdown by segment (product or service), as of Jun 26: Product (50.91%), EXPAREL (39.51%), ZILRETTA (8.73%), and Bupivacaine Liposome Injectable Suspension (0.86%).

Pacira BioSciences Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
TNDMTandem Diabetes Care$1.01B$254.56M
PCRXPacira BioSciences$726.41M$192.40M
ANABAnaptysBio$234.60M$25.56M
CRONCronos Group$193.36M$70.60M
PHATPhathom Pharmaceuticals$175.11M$74.27M
URGNUroGen Pharma$109.79M$72.46M
OCSOculis$883.00K-
KODKodiak Sciences--
BBOTBridgeBio Oncology Therapeutics--
XNCRXencor--
MNMDMind Medicine (MindMed)--

PCRX Revenue FAQ

What is Pacira BioSciences’s yearly revenue?

Pacira BioSciences's yearly revenue for 2025 was $726.41M, representing an increase of 3.63% compared to 2024. The company's yearly revenue for 2024 was $700.97M, representing an increase of 3.85% compared to 2023. PCRX's yearly revenue for 2023 was $674.98M, representing an increase of 1.22% compared to 2022.

What is Pacira BioSciences’s quarterly revenue?

Pacira BioSciences's quarterly revenue for Q2 2026 was $192.4M, a 8.47% increase from the previous quarter (Q1 2026), and a 6.24% increase year-over-year (Q2 2025). The company's quarterly revenue for Q1 2026 was $177.38M, a -9.90% decrease from the previous quarter (Q4 2025), and a 5.00% increase year-over-year (Q1 2025). PCRX's quarterly revenue for Q4 2025 was $196.87M, a 9.67% increase from the previous quarter (Q3 2025), and a 5.14% increase year-over-year (Q4 2024).

What is Pacira BioSciences’s revenue growth rate?

Pacira BioSciences's revenue growth rate for the last 3 years (2023-2025) was 7.62%, and for the last 5 years (2021-2025) was 34.14%.

What are Pacira BioSciences’s revenue streams?

Pacira BioSciences's revenue streams in c 25 are EXPAREL, Product, ZILRETTA, and Bupivacaine Liposome Injectable Suspension. EXPAREL generated $575.13M in revenue, accounting 40.46% of the company's total revenue, up 4.77% year-over-year. Product generated $722.85M in revenue, accounting 50.85% of the company's total revenue, up 3.68% year-over-year. ZILRETTA generated $116.63M in revenue, accounting 8.20% of the company's total revenue, down -1.23% year-over-year. Bupivacaine Liposome Injectable Suspension generated $6.91M in revenue, accounting 0.49% of the company's total revenue, down -5.59% year-over-year.

What is Pacira BioSciences’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Pacira BioSciences was Product. This segment made a revenue of $722.85M, representing 50.85% of the company's total revenue.